ARCHIVES

A Biostatistics Paper Alleges Potential Harm To Patients In Two Duke Clinical Studies

This article is from The Cancer Letter archive.

Vol. 35 No. 36 | October 2, 2009

Download PDF Visit The Full Archive

Related Articles

Dendritic Cell Vaccine May Boost Median Survival

March 25, 2011

FDA Approves Manufacturer Of IVAX Paclitaxel Ingredient.

June 29, 2001

FDA Considering Ways To Improve Process Of Secondary Approvals Of Cancer Drugs

November 1, 1991

Black Men Face Disparate Cancer Burden; Minority Rates Vary, Klausner Tells House

April 3, 1998

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

January 21, 2005

Can NCI Fund 4-Year Grants With 2-Year Stimulus Funds?

March 6, 2009